High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke

被引:218
作者
Elkind, Mitchell S. V.
Tai, Wanling
Coates, Kristen
Paik, Myunghee C.
Sacco, Ralph L.
机构
[1] Columbia Univ, Dept Neurol, New York, NY 10027 USA
[2] Columbia Univ, Sergievsky Ctr, New York, NY 10027 USA
[3] Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA
[4] Columbia Univ, Div Biostat, New York, NY 10027 USA
[5] Columbia Univ, Dept Epidemiol, New York, NY 10027 USA
[6] Columbia Univ, Joseph P Mailman Sch Publ Hlth, New York, NY 10027 USA
[7] New York Presbyterian Hosp, Med Ctr, New York, NY USA
关键词
D O I
10.1001/archinte.166.19.2073
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background: Inflammatory markers have been associated with ischemic stroke risk and prognosis after cardiac events. Their relationship to prognosis after stroke is unsettled. Methods: A population-based study of stroke risk factors in 467 patients with first ischemic stroke was undertaken to determine whether levels of high-sensitivity C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A(2) (Lp-PLA2) predict risk of stroke recurrence, other vascular events, and death. Results: Levels of Lp-PLA2 and hs-CRP were weakly correlated (r=0.09; P=.045). High-sensitivity CRP, but not Lp-PLA2, was associated with stroke severity. After adjusting for age, sex, race and ethnicity, history of coronary artery disease, diabetes mellitus, hypertension, hyperlipidemia, atrial fibrillation, smoking, and hs-CRP level, compared with the lowest quartile of Lp-PLA2, those in the highest quartile had an increased risk of recurrent stroke (adjusted hazard ratio, 2.08; 95% confidence interval, 1.04-4.18) and of the combined outcome of recurrent stroke, MI, or vascular death (adjusted hazard ratio, 1.86; 95% confidence interval, 1.01-3.42). After adjusting for confounders, hs-CRP was not associated with risk of recurrent stroke or recurrent stroke, myocardial infarction, or vascular death but was associated with risk of death (adjusted hazard ratio, 2.11; 95% confidence interval, 1.18-3.75). Conclusions: Inflammatory markers are associated with prognosis after first ischemic stroke and may offer complementary information. Lipoprotein-associated phospholipase A(2) may be a stronger predictor of recurrent stroke risk. Levels of hs-CRP, an acute-phase reactant, increase with stroke severity and may be associated with mortality to a greater degree than recurrence.
引用
收藏
页码:2073 / 2080
页数:8
相关论文
共 45 条
[1]
Baseline NIH Stroke Scale score strongly predicts outcome after stroke - A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST) [J].
Adams, HP ;
Davis, PH ;
Leira, EC ;
Chang, KC ;
Bendixen, BH ;
Clarke, WR ;
Woolson, RF ;
Hansen, MD .
NEUROLOGY, 1999, 53 (01) :126-131
[2]
Design of the trial of Org 10172 in acute stroke treatment (TOAST) [J].
Adams, HP ;
Woolson, RF ;
Clarke, WR ;
Davis, PH ;
Bendixen, BH ;
Love, BB ;
Wasek, PA ;
Grimsman, KJ .
CONTROLLED CLINICAL TRIALS, 1997, 18 (04) :358-377
[3]
Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[4]
C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease [J].
Arenillas, JF ;
Alvarez-Sabín, J ;
Molina, CA ;
Chacón, P ;
Montaner, J ;
Rovira, A ;
Ibarra, B ;
Quintana, M .
STROKE, 2003, 34 (10) :2463-2468
[5]
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].
Ballantyne, CM ;
Hoogeveen, RC ;
Bang, H ;
Coresh, P ;
Folsom, AR ;
Chambless, LE ;
Myerson, M ;
Wu, KK ;
Sharrett, AR ;
Boerwinkle, E .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (21) :2479-2484
[6]
Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study [J].
Ballantyne, CM ;
Hoogeveen, RC ;
Bang, H ;
Coresh, J ;
Folsom, AR ;
Heiss, G ;
Sharrett, AR .
CIRCULATION, 2004, 109 (07) :837-842
[7]
INTERLEUKIN-6 AND INTERLEUKIN-1 RECEPTOR ANTAGONIST IN ACUTE STROKE [J].
BEAMER, NB ;
COULL, BM ;
CLARK, WM ;
HAZEL, JS ;
SILBERGER, JR .
ANNALS OF NEUROLOGY, 1995, 37 (06) :800-805
[8]
The identification of clinical candidate SB-480848:: A potent inhibitor of lipoprotein-associated phospholipase A2 [J].
Blackie, JA ;
Bloomer, JC ;
Brown, MJB ;
Cheng, HY ;
Hammond, B ;
Hickey, DMB ;
Ife, RJ ;
Leach, CA ;
Lewis, VA ;
Macphee, CH ;
Milliner, KJ ;
Moores, KE ;
Pinto, IL ;
Smith, SA ;
Stansfield, IG ;
Stanway, SJ ;
Taylor, MA ;
Theobald, CJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (06) :1067-1070
[9]
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up [J].
Brilakis, ES ;
McConnell, JP ;
Lennon, RJ ;
Elesber, AA ;
Meyer, JG ;
Berger, PB .
EUROPEAN HEART JOURNAL, 2005, 26 (02) :137-144
[10]
C-reactive protein, physical disability, and prognosis in very old patients with ischemic stroke [J].
Ceccarelli, E ;
Donati, C ;
Forconi, S ;
Masotti, L .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2002, 57 (08) :M520-M522